This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rogers, A. Articles by Eastell, R. Search for Related Content PubMed PubMed Citation Articles by Rogers, A. Articles by Eastell, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB ESTRADIOL

Circulating Estradiol and Osteoprotegerin as Determinants of Bone Turnover and Bone Density in Postmenopausal Women

Bone Metabolism Group, University of Sheffield (A.R., R.A.H., D.G., R.E.), Sheffield S5 7AU; and Division of Biomedical Sciences, Sheffield Hallam University (G.S.), Sheffield S1 1WB, United Kingdom

Address all correspondence and requests for reprints to: Dr. Angela Rogers, Clinical Sciences Centre (North), Northern General Hospital, Herries Road, Sheffield S5 7AU, United Kingdom. E-mail: angela.rogers{at}sheffield.ac.uk.

Abstract

Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NFB ligand. OPG has been shown to be an important inhibitor of osteoclast differentiation and activation in rodent models. Estrogen is known to suppress bone resorption, and the action of estrogen on bone may be mediated by OPG. The relationship between endogenous estrogen and circulating OPG levels and bone status in human populations is unclear. Thus, the aim of this study was to investigate the relationship between biochemical markers of bone turnover and bone density and circulating OPG and endogenous estradiol levels in a population-based cohort of postmenopausal women.

Subjects were 180 women ages 55–91 yr (mean age, 67 yr). Serum estradiol was measured using an auto-analyzer. Serum concentrations of OPG were determined by ELISA. Markers of bone formation and resorption were measured by standard methods. Bone mineral density at total body, total hip, femoral neck, and lumbar spine was measured by dual energy x-ray absorptiometry.

There was a significant inverse relationship between estradiol and all bone turnover markers (r-values from -0.46 to -0.23; P < 0.05). Serum estradiol was positively related to absolute bone density at all sites and to change in bone density at the hip and femoral neck by univariate analysis (r-values from 0.15–0.29; P < 0.05). We observed a weak inverse association between OPG and serum-based bone turnover markers (r-values -0.18 and -0.16; P < 0.05). There was a significant positive relationship between OPG and bone mineral density at total body, total hip, and femoral neck (r-values from 0.17–0.2; P < 0.05) by univariate analysis, which was lost after adjustment for age and body mass index. There was a significant weak positive relationship between circulating OPG and serum estradiol (r = 0.18; P < 0.02). We observed no significant relationships between OPG and bone turnover markers measured in urine.

We conclude that the variation in circulating endogenous estradiol levels is an important factor contributing to levels of bone turnover and bone density at the menopause. Our observations also suggest that circulating levels of OPG may reflect OPG activity in bone and are related to circulating endogenous levels of estradiol. We have previously reported high levels of variability in urine markers of bone resorption, and we suggest that this could account for the absence of a significant association between these markers and circulating OPG.

This article has been cited by other articles:

				E. J. Samelson, K. E. Broe, S. Demissie, T. J. Beck, D. Karasik, S. Kathiresan, and D. P. Kiel Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1789 - 1795. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				R. Eastell, J. E. Adams, R. E. Coleman, A. Howell, R. A. Hannon, J. Cuzick, J. R. Mackey, M. W. Beckmann, and G. Clack Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 J. Clin. Oncol., March 1, 2008; 26(7): 1051 - 1057. [Abstract] [Full Text] [PDF]

				D. Vega, N. M. Maalouf, and K. Sakhaee The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521. [Abstract] [Full Text] [PDF]

				L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545. [Abstract] [Full Text] [PDF]

				A. Stern, G. A Laughlin, J. Bergstrom, and E. Barrett-Connor The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor {kappa}B legend with bone mineral density in older adults: the Rancho Bernardo Study Eur. J. Endocrinol., May 1, 2007; 156(5): 555 - 562. [Abstract] [Full Text] [PDF]

				J. A. Riancho, C. Valero, A. Naranjo, D. J. Morales, C. Sanudo, and M. T. Zarrabeitia Identification of an Aromatase Haplotype That Is Associated with Gene Expression and Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 660 - 665. [Abstract] [Full Text] [PDF]

				U.H. Lerner Bone Remodeling in Post-menopausal Osteoporosis Journal of Dental Research, July 1, 2006; 85(7): 584 - 595. [Abstract] [Full Text] [PDF]

				A. H. E. M. Maas, Y. T. van der Schouw, D. Beijerinck, J. J. M. Deurenberg, W. P. T. M. Mali, and Y. van der Graaf Arterial Calcifications Seen on Mammograms: Cardiovascular Risk Factors, Pregnancy, and Lactation Radiology, July 1, 2006; 240(1): 33 - 38. [Abstract] [Full Text] [PDF]

				G. Mazziotti, G. Amato, F. Sorvillo, M. Piscopo, M. R. Rizzo, E. Lalli, L. Iride, M. Cioffi, A. M. Molinari, G. Paolisso, et al. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Eur. J. Endocrinol., March 1, 2006; 154(3): 373 - 377. [Abstract] [Full Text] [PDF]

				A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]

				S. Banerjee, I. E. Smith, L. Folkerd, J. Iqbal, P. Barker, M. Dowsett, and On behalf of the IMPACT trialists Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial Ann. Onc., October 1, 2005; 16(10): 1632 - 1638. [Abstract] [Full Text] [PDF]

				L. C. Hofbauer and M. Schoppet Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases JAMA, July 28, 2004; 292(4): 490 - 495. [Abstract] [Full Text] [PDF]

				Q. Wang, P. H. F. Nicholson, M. Suuriniemi, A. Lyytikainen, E. Helkala, M. Alen, H. Suominen, and S. Cheng Relationship of Sex Hormones to Bone Geometric Properties and Mineral Density in Early Pubertal Girls J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1698 - 1703. [Abstract] [Full Text] [PDF]

				S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631. [Abstract] [Full Text] [PDF]

				K. E. Naylor, A. Rogers, R. B. Fraser, V. Hall, R. Eastell, and A. Blumsohn Serum Osteoprotegerin as a Determinant of Bone Metabolism in a Longitudinal Study of Human Pregnancy and Lactation J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5361 - 5365. [Abstract] [Full Text] [PDF]

				S. K. Grinspoon, A. J. Friedman, K. K. Miller, J. Lippman, W. H. Olson, and M. P. Warren Effects of a Triphasic Combination Oral Contraceptive Containing Norgestimate/Ethinyl Estradiol on Biochemical Markers of Bone Metabolism in Young Women with Osteopenia Secondary to Hypothalamic Amenorrhea J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3651 - 3656. [Abstract] [Full Text] [PDF]